Omeros submits its biologics license application to u.s. fda for narsoplimab in hsct-tma

Seattle--(business wire)--omeros corporation (nasdaq: omer) announced that it has completed the rolling submission of its biologics license application (bla) to the u.s. food and drug administration (fda) for narsoplimab for the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (hsct-tma). narsoplimab targets mannan-binding lectin-associated serine protease-2 (masp-2), the effector enzyme of the lectin pathway of complement, and has received breakthrough ther
OMER Ratings Summary
OMER Quant Ranking